Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients

• Published in: Experimental biology and medicine (Maywood, N.J.) N.J.), 2018-02, Vol.243 (3), p.248-255
• Main Authors: Yu, Li-Rong, Cao, Zhijun, Makhoul, Issam, Daniels, Jaclyn R, Klimberg, Suzanne, Wei, Jeanne Y, Bai, Jane PF, Li, Jinong, Lathrop, Julia T, Beger, Richard D, Todorova, Valentina K
• Format: Article
• Language: English
• Subjects: Antibiotics, Antineoplastic - therapeutic use; Antibiotics, Antineoplastic - toxicity; Biomarkers, Tumor - blood; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - immunology; Cardiotoxicity; Chemokines - blood; Doxorubicin - therapeutic use; Doxorubicin - toxicity; Female; Humans; Matrix Metalloproteinases - blood; Middle Aged; Original Research; Pilot Projects; Stroke Volume - drug effects; Ventricular Function, Left - drug effects
• ISSN: 1535-3702; 1535-3699
• DOI: 10.1177/1535370217746383

Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5–10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment). Multiplex immunoassays were used to screen plasma samples for 40 distinct chemokines, nine matrix metalloproteinases, 33 potential markers of cardiovascular diseases, and the fourth-generation cardiac troponin T assay. The results showed that the patients with abnormal decline of LVEF (>10%) had lower levels of CXCL6 and sICAM-1 and higher levels of CCL23 and CCL27 at T0; higher levels of CCL23 and lower levels of CXCL5, CCL26, CXCL6, GM-CSF, CXCL1, IFN-γ, IL-2, IL-8, CXCL11, CXCL9, CCL17, and CCL25 at T1; and higher levels of MIF and CCL23 at T2 than the patients who maintained normal LVEF. Patients with LVEF decline of 5–10% had lower plasma levels of CXCL1, CCL3, GDF-15, and haptoglobin at T0; lower levels of IL-16, FABP3, and myoglobin at T1; and lower levels of myoglobin and CCL23 at T2 as compared to the patients who maintained normal LVEF. This pilot study identified potential biomarkers that may help predict which patients are vulnerable to DOX-induced cardiotoxicity although further validation is needed in a larger cohort of patients. Impact statement Drug-induced cardiotoxicity is one of the major concerns in drug development and clinical practice. It is critical to detect potential cardiotoxicity early before onset of symptomatic cardiac dysfunction or heart failure. Currently there are no qualified clinical biomarkers for the prediction of cardiotoxicity caused by cancer treatment such as doxorubicin (DOX). By using multiplex immunoassays, we identified proteins with significantly changed plasma levels in a group of breast cancer patients who were treated with DOX-based chemotherapy and produced cardiotoxicity. These proteins were associated with immune respon